HLA has provided an update on its financial performance for FY23

Healthia Limited (ASX: HLA) issued a financial performance update for FY23, covering the 12 months ending 30 June 2023. The company expects an EBITDA(u) (pre AASB16) between AU$38.0 million to AU$39.0 million, marking a 55.5% to 59.6% increase from FY22's AU$24.5m EBITDA(u) (pre AASB16), though falling short of the previous guidance of EBITDA(u) (pre AASB16) exceeding AU$40 million.

During FY23, Healthia faced significant team member absenteeism in Financial Quarter 1 due to COVID-related illnesses and isolations. In Q4FY23, there were higher-than-expected team member absences due to COVID and influenza, impacting trading and service to patients. Despite these challenges, Healthia achieved robust organic like-for-like revenue growth compared to FY22, which also experienced staff absenteeism and patient cancellations due to COVID.

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com